We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLCO icon
276
Melco Resorts & Entertainment
MLCO
$2.14B
– –
-400,000
Closed -$3.12M
MO icon
277
Altria Group
MO
$114B
– –
-11,310
Closed -$577K
MOBX icon
278
Mobix Labs
MOBX
$26M
– –
-233,600
Closed -$2.48M
MPU icon
279
Mega Matrix
MPU
$13.7M
– –
-220,000
Closed -$222K
MRK icon
280
Merck
MRK
$318B
– –
-182,794
Closed -$20.8M
MUSA icon
281
Murphy USA
MUSA
$9.61B
– –
-6,592
Closed -$3.25M
MYSZ icon
282
My Size
MYSZ
$1.88M
– –
-78,000
Closed -$131K
NKE icon
283
Nike
NKE
$61.9B
– –
-17,986
Closed -$1.59M
OKTA icon
284
Okta
OKTA
$25.8B
– –
-4,139
Closed -$308K
ONDS icon
285
Ondas Inc
ONDS
$5.19B
– –
-4,750,000
Closed -$3.66M
PARA
286
DELISTED
Paramount Global Class B
PARA
– –
-2,000,000
Closed -$21.2M
PCTY icon
287
Paylocity
PCTY
$7.98B
– –
-1,424
Closed -$235K
PG icon
288
Procter & Gamble
PG
$339B
– –
-3,017
Closed -$523K
PIII icon
289
P3 Health Partners
PIII
$38.5M
– –
-133,000
Closed -$2.57M
PPBT
290
Purple Biotech
PPBT
$1.33M
– –
-15,800
Closed -$877K
RANI icon
291
Rani Therapeutics
RANI
$89M
– –
-2,574,000
Closed -$5.56M
RBLX icon
292
Roblox
RBLX
$27B
– –
-5,546
Closed -$245K
RNAC icon
293
Cartesian Therapeutics
RNAC
$268M
– –
-98,565
Closed -$1.59M
RVTY icon
294
Revvity
RVTY
$12.8B
– –
-107,486
Closed -$13.7M
OLOX
295
Olenox Industries
OLOX
$4.5M
– –
-95
Closed -$58.3K
SHW icon
296
Sherwin-Williams
SHW
$89.8B
– –
-723
Closed -$276K
TAP icon
297
Molson Coors Class B
TAP
$8.1B
– –
-5,836
Closed -$336K
TFX icon
298
Teleflex
TFX
$5.98B
– –
-78,000
Closed -$19.3M
TOVX icon
299
Theriva Biologics
TOVX
$10.1M
– –
-100,000
Closed -$138K
TPR icon
300
Tapestry
TPR
$32.8B
– –
-13,967
Closed -$656K
9 10 11
12
13

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.